{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:26:15Z","timestamp":1789590375501,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40259-017-0217-6","type":"journal-article","created":{"date-parts":[[2017,5,21]],"date-time":"2017-05-21T20:58:07Z","timestamp":1495400287000},"page":"263-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Golimumab: A Review in Inflammatory Arthritis"],"prefix":"10.1007","volume":"31","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"issue":"4","key":"217_CR1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","volume":"41","author":"P Mease","year":"2015","unstructured":"Mease P. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):723\u20138.","journal-title":"Rheum Dis Clin North Am"},{"key":"217_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1218761","author":"MS Osman","year":"2016","unstructured":"Osman MS, Maksymowych WP. An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis. Expert Rev Clin Immunol. 2016;. doi: 10.1080\/1744666X.2016.1218761 .","journal-title":"Expert Rev Clin Immunol."},{"issue":"1\u20132","key":"217_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","volume":"165","author":"H Radner","year":"2015","unstructured":"Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015;165(1\u20132):3\u20139.","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"217_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"217_CR5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"217_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"217_CR7","unstructured":"EMA. Simponi 50\u00a0mg solution for injection in pre-filled pen: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 21 July 2016."},{"issue":"2","key":"217_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00063030-200923020-00005","volume":"23","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs. 2009;23(2):125\u201335.","journal-title":"BioDrugs."},{"issue":"5","key":"217_CR9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/ard.2010.148890","volume":"71","author":"C Wagner","year":"2012","unstructured":"Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis. 2012;71(5):674\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"217_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/annrheumdis-2012-201697","volume":"72","author":"CL Wagner","year":"2013","unstructured":"Wagner CL, Visvanathan S, Elashoff M, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83\u20138.","journal-title":"Ann Rheum Dis"},{"key":"217_CR11","doi-asserted-by":"crossref","unstructured":"Inman RD, Baraliakos X, Hermann KA, et al. Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther. 2016;18(1):304.","DOI":"10.1186\/s13075-016-1200-1"},{"issue":"6","key":"217_CR12","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3188","volume":"12","author":"S Visvanathan","year":"2010","unstructured":"Visvanathan S, Rahman MU, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther. 2010;12(6):R211.","journal-title":"Arthritis Res Ther."},{"key":"217_CR13","unstructured":"EMA. Assessment report. Simponi. International non-proprietary name: golimumab. Procedure No.: EMEA\/H\/C\/000992\/II\/0063. 2016. http:\/\/www.ema.europa.eu . Accessed 18 Aug 2016."},{"key":"217_CR14","doi-asserted-by":"publisher","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicenter, double-blind, randomized-withdrawal trial. Ann Rheum Dis. 2017. doi: 10.1136\/annrheumdis-2016-210456","DOI":"10.1136\/annrheumdis-2016-210456"},{"issue":"6","key":"217_CR15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.22759","volume":"68","author":"P Emery","year":"2016","unstructured":"Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res. 2016;68(6):744\u201352.","journal-title":"Arthritis Care Res."},{"issue":"2","key":"217_CR16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.150712","volume":"43","author":"EC Keystone","year":"2016","unstructured":"Keystone EC, Genovese MC, Hall S, et al. Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial. J Rheumatol. 2016;43(2):298\u2013306.","journal-title":"J Rheumatol"},{"issue":"9","key":"217_CR17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5\u00a0years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"217_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","volume":"74","author":"A Deodhar","year":"2015","unstructured":"Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4\u00a0weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74(4):757\u201361.","journal-title":"Ann Rheum Dis"},{"key":"217_CR19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13075-015-0516-6","volume":"17","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17:14.","journal-title":"Arthritis Res Ther."},{"issue":"8","key":"217_CR20","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272\u201383.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"217_CR21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"217_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet"},{"issue":"5","key":"217_CR23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","volume":"63","author":"P Emery","year":"2011","unstructured":"Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200\u201310.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"217_CR24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/acr.22072","volume":"65","author":"P Emery","year":"2013","unstructured":"Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4\u00a0weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res. 2013;65(11):1732\u201342.","journal-title":"Arthritis Care Res."},{"issue":"9","key":"217_CR25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10067-014-2731-y","volume":"33","author":"P Emery","year":"2014","unstructured":"Emery P, Fleischmann RM, Hsia EC, et al. Efficacy of golimumab plus methotrexate in methotrexate-naive patients with severe active rheumatoid arthritis. Clin Rheumatol. 2014;33(9):1239\u201346.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"217_CR26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69(6):1129\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"217_CR27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3899\/jrheum.111195","volume":"39","author":"MC Genovese","year":"2012","unstructured":"Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol. 2012;39(6):1185\u201391.","journal-title":"J Rheumatol"},{"issue":"11","key":"217_CR28","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/ard.2010.146068","volume":"70","author":"PG Conaghan","year":"2011","unstructured":"Conaghan PG, Emery P, Ostergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis. 2011;70(11):1968\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"217_CR29","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976\u201386.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"217_CR30","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2\u00a0years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 2013;65(10):1666\u201373.","journal-title":"Arthritis Care Res."},{"issue":"8","key":"217_CR31","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504\u201317.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"217_CR32","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402\u201312.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"217_CR33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D Heijde van der","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, et al. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014;41(6):1095\u2013103.","journal-title":"J Rheumatol"},{"issue":"6","key":"217_CR34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012;71(6):878\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"217_CR35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4\u00a0weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5):661\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"217_CR36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","volume":"73","author":"J Braun","year":"2014","unstructured":"Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4\u00a0years of the GO-RAISE trial. Ann Rheum Dis. 2014;73(6):1107\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"217_CR37","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702\u201312.","journal-title":"Arthritis Rheumatol."},{"key":"217_CR38","doi-asserted-by":"crossref","unstructured":"Maksymowych W, Curtis SP, Dougados M, et al. Quality of life in patients with active nonradiographic axial spondyloarthritis after 16\u00a0weeks of golimumab treatment [abstract no. 2893]. Arthritis Rheumatol. 2015;67(Suppl 10).","DOI":"10.1136\/annrheumdis-2015-eular.3046"},{"key":"217_CR39","unstructured":"EMA. Extension of indication variation assessment report. Invented name: Simponi. International non-proprietary name: GOLIMUMAB. Procedure No.: EMEA\/H\/C\/000992\/II\/0061. 2015. http:\/\/www.ema.europa.eu . Accessed 18 Aug 2016."},{"key":"217_CR40","unstructured":"van der Heijde D, Dougados M, Maksymowych W, et al. Long-term tolerability and efficacy of golimumab in active nonradiographic axial spondyloarthritis: results from the open-label extension of a randomized, double-blind study [abstract no. 2854]. Arthritis Rheumatol. 2015;67(Suppl 10)."},{"issue":"Suppl 3","key":"217_CR41","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1002\/art.38569","volume":"66","author":"H Brunner","year":"2014","unstructured":"Brunner H, Ruperto N, Tzaribachev N, et al. A multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results [abstract no. 933]. Arthritis Rheumatol. 2014;66(Suppl 10):414\u20135.","journal-title":"Arthritis Rheumatol."},{"key":"217_CR42","unstructured":"Janssen Biotech Inc. SIMPONI (golimumab) injection, for subcutaneous use: US prescribing information. 2016. http:\/\/www.simponi.com . Accessed 11 Oct 2016."},{"key":"217_CR43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160420","author":"J Kay","year":"2016","unstructured":"Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2016;. doi: 10.3899\/jrheum.160420 .","journal-title":"J Rheumatol"},{"issue":"6","key":"217_CR44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2217\/17460816.2.6.587","volume":"2","author":"T Ding","year":"2007","unstructured":"Ding T, Deighton C. Complications of anti-TNF therapies. Future Rheumatol. 2007;2(6):587\u201397.","journal-title":"Future Rheumatol."},{"issue":"1","key":"217_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0000000000000053","volume":"20","author":"MC Wasko","year":"2014","unstructured":"Wasko MC, Hsia EC, Kirkham B, et al. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides. J Clin Rheumatol. 2014;20(1):1\u201310.","journal-title":"J Clin Rheumatol."},{"key":"217_CR46","unstructured":"EMA. Enbrel 25\u00a0mg powder and solvent for solution for injection: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 4 Nov 2016."},{"key":"217_CR47","unstructured":"EMA. Humira 40\u00a0mg solution for injection in pre-filled syringe: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 4 Nov 2016."},{"key":"217_CR48","unstructured":"EMA. Cimzia 200\u00a0mg solution for injection: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 4 Nov 2016."},{"key":"217_CR49","unstructured":"EMA. Remicade 100\u00a0mg powder for concentrate for solution for infusion: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 4 Nov 2016."},{"issue":"8","key":"217_CR50","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1136\/annrheumdis-2013-203229","volume":"73","author":"B Combe","year":"2014","unstructured":"Combe B, Dasgupta B, Louw I, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014;73(8):1477\u201386.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"217_CR51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40261-014-0246-6","volume":"35","author":"A Migliore","year":"2015","unstructured":"Migliore A, Bizzi E, Bernardi M, et al. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig. 2015;35(1):23\u20139.","journal-title":"Clin Drug Investig."},{"issue":"2","key":"217_CR52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10787-015-0229-0","volume":"23","author":"S Jinesh","year":"2015","unstructured":"Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology. 2015;23(2):71\u20137.","journal-title":"Inflammopharmacology"},{"issue":"4","key":"217_CR53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/2040622315582354","volume":"6","author":"EJ Kang","year":"2015","unstructured":"Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015;6(4):194\u2013203.","journal-title":"Ther Adv Chronic Dis."},{"issue":"10061","key":"217_CR54","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763\u201374.","journal-title":"Lancet"},{"issue":"12","key":"217_CR55","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","volume":"127","author":"TL Michaud","year":"2014","unstructured":"Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014;127(12):1208\u201332.","journal-title":"Am J Med"},{"issue":"4","key":"217_CR56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241\u201358.","journal-title":"BioDrugs."},{"issue":"2","key":"217_CR57","first-page":"71","volume":"7","author":"G Sylwestrzak","year":"2014","unstructured":"Sylwestrzak G, Liu J, Stephenson JJ, et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014;7(2):71\u201381.","journal-title":"Am Health Drug Benefits."},{"key":"217_CR58","first-page":"93","volume":"8","author":"TK Huynh","year":"2014","unstructured":"Huynh TK, \u00d8stergaard A, Egsmose C, et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93\u20139.","journal-title":"Patient Prefer Adherence."},{"issue":"12","key":"217_CR59","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kel369","volume":"45","author":"EL Williams","year":"2006","unstructured":"Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006;45(12):1575\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"217_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1\u201314.","journal-title":"Musculoskelet Care."},{"issue":"2","key":"217_CR61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/rheumatology\/kep354","volume":"49","author":"S Scarpato","year":"2010","unstructured":"Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology. 2010;49(2):289\u201394.","journal-title":"Rheumatology"},{"key":"217_CR62","first-page":"1101","volume":"10","author":"JM Nolla","year":"2016","unstructured":"Nolla JM, Rodriguez M, Martin-Mola E, et al. Patients\u2019 and rheumatologists\u2019 preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Preference Adherence. 2016;10:1101\u201313.","journal-title":"Patient Preference Adherence."},{"issue":"5","key":"217_CR63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clinthera.2014.02.019","volume":"36","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Ellis L, Bolge SC, et al. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther. 2014;36(5):737\u201347.","journal-title":"Clin Ther"},{"issue":"Suppl 2","key":"217_CR64","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/annrheumdis-2016-eular.3760","volume":"75","author":"P Bhoi","year":"2016","unstructured":"Bhoi P, Bessette L, Bell M, et al. Comparison of adherence and dosing interval of subcutaneous anti-TNF biologics in inflammatory arthritis from a Canadian administrative database [abstract no. 442]. Ann Rheum Dis. 2016;75(Suppl 2):1257.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"217_CR65","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen J, Svedbom A, Black CM, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987\u201395.","journal-title":"Rheumatol Int"},{"issue":"Suppl 2","key":"217_CR66","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/annrheumdis-2016-eular.4158","volume":"75","author":"KJ Aaltonen","year":"2016","unstructured":"Aaltonen KJ, Joensuu J, Piril\u00e4 L, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis in Finland [abstract no. FRI0194]. Ann Rheum Dis. 2016;75(Suppl 2):500.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"217_CR67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2016-eular.5642","volume":"75","author":"M Manara","year":"2016","unstructured":"Manara M, Favalli EG, Caporali R, et al. Two-year retention rate of golimumab for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: a retrospective analysis of the Italian Lorhen registry [abstract no. FRI0175]. Ann Rheum Dis. 2016;75(Suppl 2):492\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"217_CR68","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2016-eular.6212","volume":"75","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Caporali R, Monti S, et al. Two-year retention rate of subcutaneous anti-tumor necrosis factor agents for rheumatoid arthritis: a retrospective analysis of the Lorhen registry [abstract no. FRI0174]. Ann Rheum Dis. 2016;75(Suppl 2):492.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"217_CR69","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/annrheumdis-2016-eular.3653","volume":"75","author":"AF Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o AF, Ribeiro C, Borges J, et al. Real-life effectiveness of golimumab in biologic-na\u00efve rheumatoid arthritis patients\u2014data from reuma.pt, a Portuguese registry [abstract no. AB0297]. Ann Rheum Dis. 2016;75(Suppl 2):1001\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"217_CR70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/annrheumdis-2016-eular.6368","volume":"75","author":"D Giuseppe Di","year":"2016","unstructured":"Di Giuseppe D, Frisell T, Askling J. Effectiveness and persistence of golimumab across rheumatic disease indications in clinical practice: results from the national Swedish register [abstract no. THU0607]. Ann Rheum Dis. 2016;75(Suppl 2):411\u20132.","journal-title":"Ann Rheum Dis"},{"key":"217_CR71","unstructured":"Rotar \u017d, Tom\u0161i\u010d M. The persistence of golimumab in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: analysis of prospectively collected data in the Slovenian National Online Registry of patients treated with biologics BioRx.si [abstract no. PMS21 plus poster]. In: International Society for Pharmacoeconomics and Outcomes Research 21st Annual International Meeting. 2016."},{"issue":"8","key":"217_CR72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-013-0052-7","volume":"31","author":"J Tosh","year":"2013","unstructured":"Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(8):653\u201361.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"217_CR73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40273-013-0049-2","volume":"31","author":"N Armstrong","year":"2013","unstructured":"Armstrong N, Joore M, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(5):415\u201325.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"217_CR74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11595920-000000000-00000","volume":"30","author":"H Yang","year":"2012","unstructured":"Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257\u201370.","journal-title":"Pharmacoeconomics."},{"issue":"6","key":"217_CR75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","volume":"13","author":"E Cummins","year":"2012","unstructured":"Cummins E, Asseburg C, Prasad M, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2012;13(6):801\u20139.","journal-title":"Eur J Health Econ."},{"key":"217_CR76","unstructured":"NICE. Judging whether public health interventions offer value for money. Local government briefing [LGB10]. https:\/\/www.nice.org.uk . Accessed 16 Nov 2016."},{"key":"217_CR77","unstructured":"NICE. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. Technology appraisal guidance [TA383]. https:\/\/www.nice.org.uk . Accessed 16 Nov 2016."},{"key":"217_CR78","unstructured":"NICE. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance [TA375]. https:\/\/www.nice.org.uk . Accessed 16 Nov 2016."},{"key":"217_CR79","unstructured":"EMA. Variation assessment report. Simponi. Golimumab. Procedure No.: EMEA\/H\/C\/000992\/II\/0021. 2011. http:\/\/www.ema.europa.eu . Accessed 18 Aug 2016."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0217-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0217-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0217-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T14:46:33Z","timestamp":1750257993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0217-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0217-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}